The global point-of-care molecular diagnostics market size is expected to reach USD 10.12 billion by 2030, registering a CAGR of 2.5% from 2024 to 2030. The rising prevalence of infectious diseases such as COVID-19, HIV, HBC, HCV, along with growing geriatric population is predicted to fuel the need for POC molecular diagnostics tests. Furthermore, rapid and accurate results offered by these POC tests act as a major factor for such growing acceptance across geographies. Moreover, rising emphasis for home care and assisted care facilities across emerging economies is also predicted boost POC molecular diagnostics market growth during the forecast years. ![Global Point-of-Care Molecular Diagnostics Market]( "Global Point-of-Care Molecular Diagnostics Market")
Global geriatric population is increasing, which is expected to boost the demand for POC molecular diagnostics. Estimates published by the WHO suggest that the global population of age group 65 years and above is expected to increase from 7% in 2000 to 16% in 2050. Aging elevates the risk of diseases such as cardiovascular and cancer. Therefore, increase in global geriatric population is expected to raise the demand for continuous monitoring via facilities requiring POC MDx, such as home healthcare and assisted living healthcare facilities. Japan and China are two of the most affected Asian countries, and a significant increase in Japan’s geriatric population is anticipated. Currently, more than 20% of the country’s population is over the age of 65 years.
Increasing prevalence of cancer across countries has resulted in a continuous demand for point-of-care molecular diagnostic tests within hospitals. According to the National Center for Chronic Disease Prevention and Health Promotion, the annual cancer cases are likely to grow from 1.53 million in 2015 to 2.28 million by 2050. CDC has predicted incidence is likely to increase by 50% owing to increasing population within the U.S. Furthermore, emergence of CRISPR and NGS techniques for cancer detection has improved the diagnosis rates tremendously. With increasing affordability of NGS in past decade has also benefited the POC molecular diagnostics market for oncology. Such factors are likely to drive the global market.
Major companies active in the POC molecular diagnostics market include Danaher, BioMerieux, Bio-Rad Laboratories, Inc., Abbott, F. Hoffmann-La Roche AG, BD, and many more. Large number of pilot programs being initiated are likely to bring new products in the market. For instance, in march 2022, Intermountain Healthcare announced that they will be rolling out a Galleri Multi-Cancer Early Detection Test for 50 of their employees as a pilot plan, with this the company is expecting to launch new product in order to improve their market position.
This product will be delivered within 2 business days.
Global geriatric population is increasing, which is expected to boost the demand for POC molecular diagnostics. Estimates published by the WHO suggest that the global population of age group 65 years and above is expected to increase from 7% in 2000 to 16% in 2050. Aging elevates the risk of diseases such as cardiovascular and cancer. Therefore, increase in global geriatric population is expected to raise the demand for continuous monitoring via facilities requiring POC MDx, such as home healthcare and assisted living healthcare facilities. Japan and China are two of the most affected Asian countries, and a significant increase in Japan’s geriatric population is anticipated. Currently, more than 20% of the country’s population is over the age of 65 years.
Increasing prevalence of cancer across countries has resulted in a continuous demand for point-of-care molecular diagnostic tests within hospitals. According to the National Center for Chronic Disease Prevention and Health Promotion, the annual cancer cases are likely to grow from 1.53 million in 2015 to 2.28 million by 2050. CDC has predicted incidence is likely to increase by 50% owing to increasing population within the U.S. Furthermore, emergence of CRISPR and NGS techniques for cancer detection has improved the diagnosis rates tremendously. With increasing affordability of NGS in past decade has also benefited the POC molecular diagnostics market for oncology. Such factors are likely to drive the global market.
Major companies active in the POC molecular diagnostics market include Danaher, BioMerieux, Bio-Rad Laboratories, Inc., Abbott, F. Hoffmann-La Roche AG, BD, and many more. Large number of pilot programs being initiated are likely to bring new products in the market. For instance, in march 2022, Intermountain Healthcare announced that they will be rolling out a Galleri Multi-Cancer Early Detection Test for 50 of their employees as a pilot plan, with this the company is expecting to launch new product in order to improve their market position.
Point-of-Care Molecular Diagnostics Market Report Highlights
- By technology, the PCR-based segment held a larger share of the point-of-care molecular diagnostics market owing to increasing demand for RT-PCR tests for diagnosis of COVID-19 and other infectious diseases
- The POC test location segment is expected to grow lucratively over the forecast period due to rising demand from hospitals, clinics and ambulatory centers opting for rapid POC tests
- North America dominated the global market in 2023, owing to increasing demand for new technologies, a large pool of key players, rising prevalence of cancer, infectious diseases, and advanced healthcare infrastructure
- The Asia-Pacific is expected to grow considerably in the future owing to due to the growing healthcare infrastructure and rising awareness of cancer testing within the region
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology And Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.5. Market Restraint Analysis
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.5. Market Restraint Analysis
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
4.1. Point-of-Care Molecular Diagnostics market: Technology Movement Analysis
4.2. PCR-based
4.2.1. PCR-based Market, 2018-2030 (USD Million)
4.3. Genetic Sequencing-based
4.3.1. Genetic Sequencing-based Market, 2018-2030 (USD Million)
4.4. Hybridization-based
4.4.1. Hybridization-based Market, 2018-2030 (USD Million)
4.5. Microarray-based
4.5.1. Microarray-based Market, 2018-2030 (USD Million)
4.2. PCR-based
4.2.1. PCR-based Market, 2018-2030 (USD Million)
4.3. Genetic Sequencing-based
4.3.1. Genetic Sequencing-based Market, 2018-2030 (USD Million)
4.4. Hybridization-based
4.4.1. Hybridization-based Market, 2018-2030 (USD Million)
4.5. Microarray-based
4.5.1. Microarray-based Market, 2018-2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
5.2. Infectious Diseases
5.2.1. Infectious Diseases Market, 2018-2030 (USD Million)
5.2.2. HIV POC
5.2.2.1. HIV POC Market, 2018-2030 (USD Million)
5.2.3. Clostridium difficile POC
5.2.3.1. Clostridium difficile POC Market, 2018-2030 (USD Million)
5.2.4. HBV POC
5.2.4.1. HBV POC Market, 2018-2030 (USD Million)
5.2.5. Pneumonia or Streptococcus associated infections
5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2018-2030 (USD Million)
5.2.6. Respiratory Syncytial Virus (RSV) POC
5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2018-2030 (USD Million)
5.2.7. HPV POC
5.2.7.1. HPV POC Market, 2018-2030 (USD Million)
5.2.8. Influenza/Flu POC
5.2.8.1. Influenza/Flu POC Market, 2018-2030 (USD Million)
5.2.9. HCV POC
5.2.9.1. HCV POC Market, 2018-2030 (USD Million)
5.2.10. MRSA POC
5.2.10.1. MRSA POC Market, 2018-2030 (USD Million)
5.2.11. TB and drug-resistant TB POC
5.2.11.1. TB and drug-resistant TB POC Market, 2018-2030 (USD Million)
5.2.12. HSV POC
5.2.12.1. HSV POC Market, 2018-2030 (USD Million)
5.2.13. Other Infectious Diseases
5.2.13.1. Other Infectious Diseases Market, 2018-2030 (USD Million)
5.3. Oncology
5.3.1. Oncology Market, 2018-2030 (USD Million)
5.4. Hematology
5.4.1. Hematology Market, 2018-2030 (USD Million)
5.5. Prenatal Testing
5.5.1. Prenatal Testing Market, 2018-2030 (USD Million)
5.6. Endocrinology
5.6.1. Endocrinology Market, 2018-2030 (USD Million)
5.7. Others
5.7.1. Others Market, 2018-2030 (USD Million)
5.2. Infectious Diseases
5.2.1. Infectious Diseases Market, 2018-2030 (USD Million)
5.2.2. HIV POC
5.2.2.1. HIV POC Market, 2018-2030 (USD Million)
5.2.3. Clostridium difficile POC
5.2.3.1. Clostridium difficile POC Market, 2018-2030 (USD Million)
5.2.4. HBV POC
5.2.4.1. HBV POC Market, 2018-2030 (USD Million)
5.2.5. Pneumonia or Streptococcus associated infections
5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2018-2030 (USD Million)
5.2.6. Respiratory Syncytial Virus (RSV) POC
5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2018-2030 (USD Million)
5.2.7. HPV POC
5.2.7.1. HPV POC Market, 2018-2030 (USD Million)
5.2.8. Influenza/Flu POC
5.2.8.1. Influenza/Flu POC Market, 2018-2030 (USD Million)
5.2.9. HCV POC
5.2.9.1. HCV POC Market, 2018-2030 (USD Million)
5.2.10. MRSA POC
5.2.10.1. MRSA POC Market, 2018-2030 (USD Million)
5.2.11. TB and drug-resistant TB POC
5.2.11.1. TB and drug-resistant TB POC Market, 2018-2030 (USD Million)
5.2.12. HSV POC
5.2.12.1. HSV POC Market, 2018-2030 (USD Million)
5.2.13. Other Infectious Diseases
5.2.13.1. Other Infectious Diseases Market, 2018-2030 (USD Million)
5.3. Oncology
5.3.1. Oncology Market, 2018-2030 (USD Million)
5.4. Hematology
5.4.1. Hematology Market, 2018-2030 (USD Million)
5.5. Prenatal Testing
5.5.1. Prenatal Testing Market, 2018-2030 (USD Million)
5.6. Endocrinology
5.6.1. Endocrinology Market, 2018-2030 (USD Million)
5.7. Others
5.7.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Test Location Business Analysis
6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
6.2. OTC
6.2.1. OTC Market, 2018-2030 (USD Million)
6.3. POC
6.3.1. POC Market, 2018-2030 (USD Million)
6.2. OTC
6.2.1. OTC Market, 2018-2030 (USD Million)
6.3. POC
6.3.1. POC Market, 2018-2030 (USD Million)
Chapter 7. End-use Business Analysis
7.1. Point-of-Care Molecular Diagnostics Market: End-Use Movement Analysis
7.2. Decentralized Labs
7.2.1. Decentralized Labs Market, 2018-2030 (USD Million)
7.3. Hospitals
7.3.1. Hospitals Market, 2018-2030 (USD Million)
7.4. Home-care
7.4.1. Home-care Market, 2018-2030 (USD Million)
7.5. Assisted Living Healthcare Facilities
7.5.1. Assisted Living Healthcare Facilities Market, 2018-2030 (USD Million)
7.6. Others
7.6.1. Others Market, 2018-2030 (USD Million)
7.2. Decentralized Labs
7.2.1. Decentralized Labs Market, 2018-2030 (USD Million)
7.3. Hospitals
7.3.1. Hospitals Market, 2018-2030 (USD Million)
7.4. Home-care
7.4.1. Home-care Market, 2018-2030 (USD Million)
7.5. Assisted Living Healthcare Facilities
7.5.1. Assisted Living Healthcare Facilities Market, 2018-2030 (USD Million)
7.6. Others
7.6.1. Others Market, 2018-2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Point-of-Care Molecular Diagnostics Market Share By Region, 2023 & 2030
8.2. North America
8.2.1. North America Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Competitive Scenario
8.2.2.4. Regulatory Framework
8.2.2.5. Reimbursement Scenario
8.2.2.6. U.S. Point-of-Care Molecular Diagnostics market, 2018-2030 (USD MILLION)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. Canada Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3. Europe
8.3.1. Europe Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Target Disease Prevalence
8.3.2.3. Competitive Scenario
8.3.2.4. Regulatory Framework
8.3.2.5. Reimbursement Scenario
8.3.2.6. Germany Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. UK Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. France Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. Italy Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Spain Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Denmark Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Sweden Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Norway Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4. Asia-Pacific
8.4.1. Asia-Pacific Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Competitive Scenario
8.4.2.4. Regulatory Framework
8.4.2.5. Reimbursement Scenario
8.4.2.6. Japan Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. China Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. India Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. South Korea Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. Australia Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Thailand Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Competitive Scenario
8.5.2.4. Regulatory Framework
8.5.2.5. Reimbursement Scenario
8.5.2.6. Brazil Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Mexico Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Argentina Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6. MEA
8.6.1. MEA Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Competitive Scenario
8.6.2.4. Regulatory Framework
8.6.2.5. Reimbursement Scenario
8.6.2.6. South Africa Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. Saudi Arabia Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. UAE Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. Kuwait Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.2. North America
8.2.1. North America Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Competitive Scenario
8.2.2.4. Regulatory Framework
8.2.2.5. Reimbursement Scenario
8.2.2.6. U.S. Point-of-Care Molecular Diagnostics market, 2018-2030 (USD MILLION)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. Canada Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3. Europe
8.3.1. Europe Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Target Disease Prevalence
8.3.2.3. Competitive Scenario
8.3.2.4. Regulatory Framework
8.3.2.5. Reimbursement Scenario
8.3.2.6. Germany Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. UK Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. France Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. Italy Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Spain Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Denmark Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Sweden Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Norway Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4. Asia-Pacific
8.4.1. Asia-Pacific Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Competitive Scenario
8.4.2.4. Regulatory Framework
8.4.2.5. Reimbursement Scenario
8.4.2.6. Japan Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. China Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. India Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. South Korea Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. Australia Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Thailand Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Competitive Scenario
8.5.2.4. Regulatory Framework
8.5.2.5. Reimbursement Scenario
8.5.2.6. Brazil Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Mexico Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Argentina Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6. MEA
8.6.1. MEA Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Competitive Scenario
8.6.2.4. Regulatory Framework
8.6.2.5. Reimbursement Scenario
8.6.2.6. South Africa Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. Saudi Arabia Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. UAE Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. Kuwait Point-of-Care Molecular Diagnostics market, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Point-of-Care Molecular Diagnostics market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Abbott
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Bayer AG
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. F. Hoffmann-La Roche AG
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Nova Biomedical
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. QIAGEN
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Nipro Diagnostics
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. Danaher
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Bio-Rad Laboratories, Inc.
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. bioMérieux
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. Agilent Technologies, Inc.
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.3.11. Abaxis
9.3.3.11.1. Company Overview
9.3.3.11.2. Financial Performance
9.3.3.11.3. Product Benchmarking
9.3.3.11.4. Strategic Initiatives
9.3.3.12. OraSure Technologies
9.3.3.12.1. Company Overview
9.3.3.12.2. Financial Performance
9.3.3.12.3. Product Benchmarking
9.3.3.12.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Point-of-Care Molecular Diagnostics market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Abbott
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Bayer AG
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. F. Hoffmann-La Roche AG
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Nova Biomedical
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. QIAGEN
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Nipro Diagnostics
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. Danaher
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Bio-Rad Laboratories, Inc.
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. bioMérieux
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. Agilent Technologies, Inc.
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.3.11. Abaxis
9.3.3.11.1. Company Overview
9.3.3.11.2. Financial Performance
9.3.3.11.3. Product Benchmarking
9.3.3.11.4. Strategic Initiatives
9.3.3.12. OraSure Technologies
9.3.3.12.1. Company Overview
9.3.3.12.2. Financial Performance
9.3.3.12.3. Product Benchmarking
9.3.3.12.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others
List of Tables
TABLE 1 Point-of-care Molecular Diagnostics market - Industry Snapshot & Key Buying Criteria, 2018-2030
TABLE 2 Global Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 3 Global Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 4 Global Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 5 Global Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 6 Global Point-of-care Molecular Diagnostics market, by region, 2018-2030 (USD Million)
TABLE 7 Point-of-care Molecular Diagnostics- Key market driver analysis
TABLE 8 Point-of-care Molecular Diagnostics- Key market restraint analysis
TABLE 9 North America Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 10 North America Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 11 North America Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 12 North America Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 13 North America Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 14 US Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 15 US Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 16 US Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 17 US Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 18 Canada Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 19 Canada Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 20 Canada Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 21 Canada Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 22 Europe Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 23 Europe Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 24 Europe Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 25 Europe Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 26 Europe Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 27 Germany Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 28 Germany Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 29 Germany Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 30 Germany Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 31 UK Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 32 UK Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 33 UK Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 34 UK Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 35 France Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 36 France Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 37 France Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 38 France Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 39 Italy Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 40 Italy Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 41 Italy Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 42 Italy Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 43 Spain Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 44 Spain Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 45 Spain Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 46 Spain Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 47 Denmark Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 48 Denmark Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 49 Denmark Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 50 Denmark Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 51 Sweden Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 52 Sweden Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 53 Sweden Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 54 Sweden Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 55 Norway Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 56 Norway Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 57 Norway Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 58 Norway Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 59 Asia-Pacific Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 60 Asia-Pacific Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 61 Asia-Pacific Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 62 Asia-Pacific Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 63 Asia-Pacific Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 64 Japan Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 65 Japan Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 66 Japan Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 67 Japan Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 68 China Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 69 China Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 70 China Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 71 China Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 72 India Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 73 India Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 74 India Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 75 India Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 76 Australia Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 77 Australia Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 78 Australia Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 79 Australia Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 80 South Korea Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 81 South Korea Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 82 South Korea Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 83 South Korea Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 84 Thailand Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 85 Thailand Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 86 Thailand Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 87 Thailand Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 88 Latin America Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 89 Latin America Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 90 Latin America Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 91 Latin America Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 92 Latin America Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 93 Brazil Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 94 Brazil Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 95 Brazil Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 96 Brazil Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 97 Mexico Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 98 Mexico Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 99 Mexico Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 100 Mexico Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 101 Argentina Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 102 Argentina Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 103 Argentina Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 104 Argentina Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 105 MEA Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 106 MEA Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 107 MEA Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 108 MEA Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 109 MEA Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 110 South Africa Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 111 South Africa Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 112 South Africa Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 113 South Africa Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 114 Saudi Arabia Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 115 Saudi Arabia Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 116 Saudi Arabia Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 117 Saudi Arabia Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 118 UAE Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 119 UAE Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 120 UAE Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 121 UAE Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 122 Kuwait Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 123 Kuwait Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 124 Kuwait Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 125 Kuwait Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 2 Global Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 3 Global Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 4 Global Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 5 Global Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 6 Global Point-of-care Molecular Diagnostics market, by region, 2018-2030 (USD Million)
TABLE 7 Point-of-care Molecular Diagnostics- Key market driver analysis
TABLE 8 Point-of-care Molecular Diagnostics- Key market restraint analysis
TABLE 9 North America Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 10 North America Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 11 North America Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 12 North America Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 13 North America Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 14 US Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 15 US Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 16 US Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 17 US Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 18 Canada Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 19 Canada Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 20 Canada Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 21 Canada Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 22 Europe Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 23 Europe Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 24 Europe Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 25 Europe Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 26 Europe Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 27 Germany Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 28 Germany Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 29 Germany Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 30 Germany Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 31 UK Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 32 UK Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 33 UK Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 34 UK Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 35 France Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 36 France Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 37 France Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 38 France Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 39 Italy Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 40 Italy Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 41 Italy Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 42 Italy Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 43 Spain Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 44 Spain Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 45 Spain Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 46 Spain Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 47 Denmark Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 48 Denmark Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 49 Denmark Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 50 Denmark Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 51 Sweden Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 52 Sweden Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 53 Sweden Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 54 Sweden Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 55 Norway Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 56 Norway Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 57 Norway Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 58 Norway Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 59 Asia-Pacific Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 60 Asia-Pacific Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 61 Asia-Pacific Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 62 Asia-Pacific Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 63 Asia-Pacific Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 64 Japan Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 65 Japan Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 66 Japan Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 67 Japan Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 68 China Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 69 China Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 70 China Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 71 China Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 72 India Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 73 India Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 74 India Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 75 India Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 76 Australia Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 77 Australia Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 78 Australia Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 79 Australia Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 80 South Korea Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 81 South Korea Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 82 South Korea Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 83 South Korea Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 84 Thailand Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 85 Thailand Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 86 Thailand Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 87 Thailand Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 88 Latin America Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 89 Latin America Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 90 Latin America Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 91 Latin America Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 92 Latin America Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 93 Brazil Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 94 Brazil Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 95 Brazil Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 96 Brazil Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 97 Mexico Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 98 Mexico Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 99 Mexico Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 100 Mexico Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 101 Argentina Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 102 Argentina Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 103 Argentina Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 104 Argentina Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 105 MEA Point-of-care Molecular Diagnostics market, by country, 2018-2030 (USD Million)
TABLE 106 MEA Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 107 MEA Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 108 MEA Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 109 MEA Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 110 South Africa Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 111 South Africa Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 112 South Africa Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 113 South Africa Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 114 Saudi Arabia Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 115 Saudi Arabia Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 116 Saudi Arabia Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 117 Saudi Arabia Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 118 UAE Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 119 UAE Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 120 UAE Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 121 UAE Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
TABLE 122 Kuwait Point-of-care Molecular Diagnostics market, by application, 2018-2030 (USD Million)
TABLE 123 Kuwait Point-of-care Molecular Diagnostics market, by technology, 2018-2030 (USD Million)
TABLE 124 Kuwait Point-of-care Molecular Diagnostics market, by test location, 2018-2030 (USD Million)
TABLE 125 Kuwait Point-of-care Molecular Diagnostics market, by End-use, 2018-2030 (USD Million)
List of Figures
Figure 1 Point-of-care Molecular Diagnostics Market Segmentation
Figure 2 Global Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 3 Point-of-care Molecular Diagnostics Market Dynamics
Figure 4 Key opportunities prioritized, 2018
Figure 5 Point-of-care Molecular Diagnostics Market - Porter’s Analysis
Figure 6 Point-of-care Molecular Diagnostics Market - PESTEL analysis
Figure 7 Point-of-care Molecular Diagnostics revenue share, by application, 2023 & 2030
Figure 8 POC MDx Infectious Diseases Market, 2018-2030 (USD Million)
Figure 9 POC MDx Oncology Market, 2018-2030 (USD Million)
Figure 10 POC MDx Hematology Market, 2018-2030 (USD Million)
Figure 11 POC MDx Prenatal Testing Market, 2018-2030 (USD Million)
Figure 12 POC MDx Endocrinology Market, 2018-2030 (USD Million)
Figure 13 POC MDx Other Applications Market, 2018-2030 (USD Million)
Figure 14 Point-of-care Molecular Diagnostics revenue share, by technology, 2023 & 2030
Figure 15 POC MDx PCR-based Market, 2018-2030 (USD Million)
Figure 16 POC MDx Genetic Sequencing-based Market, 2018-2030 (USD Million)
Figure 17 POC MDx Hybridization-based Market, 2018-2030 (USD Million)
Figure 18 POC MDx Microarray-based Market, 2018-2030 (USD Million)
Figure 19 Point-of-care Molecular Diagnostics revenue share, by test location, 2023 & 2030
Figure 20 POC MDx over-the-counter Market, 2018-2030 (USD Million)
Figure 21 POC MDx point-of-care Market, 2018-2030 (USD Million)
Figure 22 Point-of-care Molecular Diagnostics revenue share, by End-use, 2023 & 2030
Figure 23 POC MDx Decentralized Labs Market, 2018-2030 (USD Million)
Figure 24 POC MDx Hospitals Market, 2018-2030 (USD Million)
Figure 25 POC MDx Home-care Market, 2018-2030 (USD Million)
Figure 26 POC MDx Assisted Living Healthcare Facilities Market, 2018-2030 (USD Million)
Figure 27 POC MDx Other uses Market, 2018-2030 (USD Million)
Figure 28 Point-of-care Molecular Diagnostics revenue share, by test location, 2023 & 2030
Figure 29 POC MDx OTC Market, 2018-2030 (USD Million)
Figure 30 POC MDx POC Market, 2018-2030 (USD Million)
Figure 31 Point-of-care Molecular Diagnostics revenue share, by region, 2023 & 2030
Figure 32 North America Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 33 US Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 34 Canada Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 35 Europe Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 36 Germany Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 37 UK Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 38 France Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 39 Italy Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 40 Spain Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 41 Denmark Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 42 Sweden Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 43 Norway Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 44 Asia-Pacific Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 45 Japan Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 46 China Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 47 India Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 48 Australia Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 49 South Korea Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 50 Thailand Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 51 Latin America Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 52 Brazil Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 53 Mexico Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 54 Argentina Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 55 MEA Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 56 South Africa Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 57 Saudi Arabia Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 58 UAE Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 59 Kuwait Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 2 Global Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 3 Point-of-care Molecular Diagnostics Market Dynamics
Figure 4 Key opportunities prioritized, 2018
Figure 5 Point-of-care Molecular Diagnostics Market - Porter’s Analysis
Figure 6 Point-of-care Molecular Diagnostics Market - PESTEL analysis
Figure 7 Point-of-care Molecular Diagnostics revenue share, by application, 2023 & 2030
Figure 8 POC MDx Infectious Diseases Market, 2018-2030 (USD Million)
Figure 9 POC MDx Oncology Market, 2018-2030 (USD Million)
Figure 10 POC MDx Hematology Market, 2018-2030 (USD Million)
Figure 11 POC MDx Prenatal Testing Market, 2018-2030 (USD Million)
Figure 12 POC MDx Endocrinology Market, 2018-2030 (USD Million)
Figure 13 POC MDx Other Applications Market, 2018-2030 (USD Million)
Figure 14 Point-of-care Molecular Diagnostics revenue share, by technology, 2023 & 2030
Figure 15 POC MDx PCR-based Market, 2018-2030 (USD Million)
Figure 16 POC MDx Genetic Sequencing-based Market, 2018-2030 (USD Million)
Figure 17 POC MDx Hybridization-based Market, 2018-2030 (USD Million)
Figure 18 POC MDx Microarray-based Market, 2018-2030 (USD Million)
Figure 19 Point-of-care Molecular Diagnostics revenue share, by test location, 2023 & 2030
Figure 20 POC MDx over-the-counter Market, 2018-2030 (USD Million)
Figure 21 POC MDx point-of-care Market, 2018-2030 (USD Million)
Figure 22 Point-of-care Molecular Diagnostics revenue share, by End-use, 2023 & 2030
Figure 23 POC MDx Decentralized Labs Market, 2018-2030 (USD Million)
Figure 24 POC MDx Hospitals Market, 2018-2030 (USD Million)
Figure 25 POC MDx Home-care Market, 2018-2030 (USD Million)
Figure 26 POC MDx Assisted Living Healthcare Facilities Market, 2018-2030 (USD Million)
Figure 27 POC MDx Other uses Market, 2018-2030 (USD Million)
Figure 28 Point-of-care Molecular Diagnostics revenue share, by test location, 2023 & 2030
Figure 29 POC MDx OTC Market, 2018-2030 (USD Million)
Figure 30 POC MDx POC Market, 2018-2030 (USD Million)
Figure 31 Point-of-care Molecular Diagnostics revenue share, by region, 2023 & 2030
Figure 32 North America Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 33 US Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 34 Canada Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 35 Europe Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 36 Germany Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 37 UK Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 38 France Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 39 Italy Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 40 Spain Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 41 Denmark Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 42 Sweden Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 43 Norway Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 44 Asia-Pacific Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 45 Japan Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 46 China Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 47 India Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 48 Australia Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 49 South Korea Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 50 Thailand Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 51 Latin America Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 52 Brazil Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 53 Mexico Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 54 Argentina Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 55 MEA Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 56 South Africa Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 57 Saudi Arabia Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 58 UAE Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Figure 59 Kuwait Point-of-care Molecular Diagnostics Market, 2018-2030 (USD Million)
Companies Mentioned
- Abbott
- Bayer AG
- F. Hoffmann-La Roche AG
- Nova Biomedical
- QIAGEN
- Nipro Diagnostics
- Danaher
- Bio-Rad Laboratories, Inc.
- bioMérieux
- Agilent Technologies, Inc.
- Abaxis
- OraSure Technologies
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | December 2023 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 8.17 Billion |
| Forecasted Market Value ( USD | $ 10.12 Billion |
| Compound Annual Growth Rate | 2.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
![In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030 - Product Image](http://www.researchandmarkets.com/product_images/12002/12002788_60px_jpg/invitro_diagnostics_market.jpg)
